Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN
NCT04857957
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
46
Enrollment
INDUSTRY
Sponsor class
Conditions
Painful Diabetic Neuropathy
Interventions
DRUG:
Oral dose CNTX-6016 or oral dose Placebo
Sponsor
Centrexion Therapeutics